Trial | NCT00461617  Report issue

Title

Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients
Multicentre, Double-Dummy, Randomized, Double-Blind Comparison Between Mitiglinide and Nateglinide in the Patients With Type 2 Diabetes

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    291
The purpose of this study is to evaluate the efficacy and safety of Mitiglinide compared to Nateglinide for the treatment of type 2 diabetes.
Study Started
Aug 31
2006
Primary Completion
Jul 31
2007
Study Completion
Jul 31
2007
Last Update
Oct 21
2008
Estimate

Drug Mitiglinide

10mg tablet, 10mg TID

  • Other names: Glufast

2 Active Comparator

Nateglinide 120 mg TID

Criteria 

Inclusion Criteria:

Type 2 diabetes patients with inadequate control of blood glucose with diet and/or exercise therapy

Exclusion Criteria:

Type 1 diabetes patients
Patients who require treatment with insulin
Patients with severe diabetic complications (neuropathy, retinopathy or nephropathy)
Patients with severe ketosis, diabetic coma or precoma
Patients complicated with severe hepatic diseases
Patients complicated with severe renal diseases
Patients complicated with severe hypertension
Patients complicated with severe cardiac disease
Pregnant women or women possible to be pregnant, nursing women, or women who want to become pregnant during the study period
No Results Posted